Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 55: 1510-1516, 2009. First published June 11, 2009; 10.1373/clinchem.2009.124370
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2009.124370v1
55/8/1510    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Giarin, M. M.
Right arrow Articles by Boccadoro, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giarin, M. M.
Right arrow Articles by Boccadoro, M.
(Clinical Chemistry. 2009;55:1510-1516.)
© 2009 American Association for Clinical Chemistry, Inc.

Clinical Immunology

Serum Free Light Chain Ratio, Total {kappa}/{lambda} Ratio, and Immunofixation Results Are Not Prognostic Factors after Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma

Manuela M. Giarin1,a, Luisa Giaccone1, Roberto Sorasio1, Christian Sfiligoi1, Barbara Amoroso2, Federica Cavallo1, Alessia Cipriani1, Antonio Palumbo1 and Mario Boccadoro1

1 Divisione di Ematologia Universitaria, Azienda Ospedaliera San Giovanni Battista di Torino, Italy; 2 The Binding Site, Rome, Italy.

aAddress correspondence to this author at: Divisione di Ematologia Universitaria, Azienda Ospedaliera San Giovanni Battista di Torino, Via Genova, 3, 10126 Torino, Italy. Fax +39-11-676052; e-mail mgiarin{at}molinette.piemonte.it.

Background: The prognostic value of changes in paraprotein markers after stem cell transplantation is unknown. We evaluated disease response using serum immunofixation (s-IFIX), total {kappa} and {lambda} ratio (KLR), and free light chain (FLC) ratio in myeloma patients who underwent autologous or autologous plus allogeneic stem cell transplantation.

Methods: We studied s-IFIX, KLR, and FLC ratio in sera from 203 patients, 3 months after transplantation. We evaluated overall and event-free survival (OS and EFS, interval between date of study enrollment and date of death from any cause or date of progression, relapse, or death from any cause, respectively) by the Kaplan–Meier method.

Results: Of the 203 patients, 51 were negative by s-IFIX, 99 reached a normal KLR, and 92 had a normal FLC ratio. Of the 51 patients with negative s-IFIX, 40 (78%) also had a normal FLC ratio. The median duration of OS was 54.3 months, and the median EFS was 19.5 months. None of the measured paraprotein parameters showed an association with OS. Only a normal KLR was associated with prolonged EFS (P = 0.016). Even a negative s-IFIX associated with a normal FLC ratio did not show a significant difference in terms of EFS and OS.

Conclusions: Our analysis with a small cohort of patients did not show a significant impact of achieving complete response (CR) or stringent CR on patient survival.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American Association for Clinical Chemistry.